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Lettersproduction of cells that are to be used
clinically will have to be provided when
organizations seek regulatory approval.
By contrast, patents provide transpar-
ency and thus facilitate competition and
progress.
The judgment refers only to ESCs, and
a great deal of research is being carried
out with other types of stem cells. A stated
objective of Greenpeace UK is to bring
pressure to increase research with alter-natives to hESCs. There is no doubt that
researchers do consider alternatives and
that great interest is placed upon iPSCs.
Patent applications made in the future
can encompass both sources of pluripo-
tent cells, but iPSCs are a relatively new
invention, so early applications such as
that made by Oliver Bru¨stle did not. It
would be wasteful and it would delay
treatment of patients if existing protocols
for use of hESC derivatives are not takenCell Stem Cell 9,to the clinic because the procedure
cannot be patented.
Finally, there is a real concern that
Europe will be perceived as reactionary
and resistant to progress in light of this
regulation and that as a result, companies
will choose to invest in other regions of the
world. It is certainly to be hoped that this is
not the case, because Europe has a fine
record of research with both embryonic
and tissue stem cells.European Court Ruling on Embryonic Stem Cells:
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DOI 10.1016/j.stem.2011.11.001The recentCourt of Justiceof the European
Union (2011) opinion in Bru¨stle v. Green-
peace caught the attention of the California
Institute for Regenerative Medicine (CIRM)
and many others as a result of its severe
restriction on the patentability of inventions
arising from embryonic-stem-cell-related
research. Strong criticism of the decision
immediately arose in some quarters, in-
cluding dire predictions that the ruling
marked the end of human embryonic stem
cell (hESC) research in Europe and, ulti-
mately, that Europewould not have access
to resulting therapies (Naik, 2011). At CIRM
we fund academic and commercial scien-
tists conducting stem cell research ranging
from basic science through to early clinical
work, and a significant proportion of our
funded projects involve hESCs. We appre-
ciate that patent protection can be an
important incentive for investment, and
that it also often promotes innovation as it
allows innovators time and a mechanism
to recoup their outlay (Rai et al., 2010).
Our view is that the impact of the recent
Court ruling on stem cell research and
regenerative medicine will be significant
but varied. In some instances, the ruling
may deter European hESC research, in
others such research may nonetheless
continue or even increase; in still others,
no impact may occur.In the area of basic or foundational
hESC research, for example, we would
not expect a significant impact from the
Court ruling provided scientists expect
that there will be continued funding of
such research by government and not-
for-profit entities. We would not expect
that a diminished ability to obtain patent
protection for basic research inventions
would materially decrease research fund-
ing from these sources. Government
funders tend to be less profit-driven than
commercial funders. Moreover, hESCs
presently remain the ‘‘gold standard’’ for
regenerative medicine research (Smith
et al., 2009; Fung and Kerridge, 2011).
We believe scientists conducting basic
research will be reluctant to focus exclu-
sively on adult stem cells or even induced
pluripotent stem cells (iPSCs) given the
unique advantages offered by hESCs.
With respect to translational hESC
research, the situation is more compli-
cated. At this stage of research and devel-
opment, profit-driven biotechnology and
pharmaceutical companies are more
actively involved. To the extent that the
lack of patent protection following the
Court ruling decreases the profit available
(e.g., because patented inventions cannot
be licensed and injunctions cannot be
obtained to protect hESC patented inven-tions), biotechnology and pharmaceutical
companies may be less motivated to
invest in European hESC research. That
effect may be even more dramatic for
startup companies. A strong patent port-
folio traditionally has been a prerequisite
for attracting venture capital in the life
sciences field. As reported by a U.S
Department of Commerce white paper,
‘‘In a large-scale survey conducted in
2008, 76% of startup managers reported
that VC investors consider patents impor-
tant to funding decisions.’’ (Rai et al.,
2010.)
On the other hand,wewould not predict
a complete dearth of European commer-
cial investment in the hESC sector in the
EU for several reasons. First, companies
can still protect some of their work as
traditional trade secrets. Second, as is
often said of biologics, ‘‘The product is
the process.’’ EU regulators will likely
require that any company wishing to
compete would have to incur the large
expense of preclinical and clinical trials
using their particular stem-cell-based
therapy (Tam, 2010). Third, to varying
degrees throughout Europe, the ‘‘Bolar
Exemption’’ (European Union, 2004)
limited patent protection for certain types
of research at this phase even before
the Court ruling. Finally, the effect of theDecember 2, 2011 ª2011 Elsevier Inc. 499
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LettersCourt ruling on EUcompanieswill vary de-
pending on their specific circumstances.
Companies that would have faced a
freedom to operate problem because of
hESC patents held by others may now
be more likely to start, or continue, hESC
research programs because the Court’s
ruling renders such patents unenforce-
able. Companies working on the ‘‘im-
provement’’ of hESC related-technolo-
gies, for instance, which would have
faced patent infringement litigation or
would have had to pay royalties, may
find themselves more incentivized to
performhESC research in theEU following
theCourt’s ruling. By contrast, companies
holding foundational hESC inventions
might be incentivized to work in jurisdic-
tions that offer patent protection for
hESC inventions (e.g., the USA).
Despite the Court ruling we believe that
sponsors of hESC-based therapies will
locate trials in Europe for a number of
reasons. Companies developing hESC
therapies will ultimately desire to sell their
products on the European market. The
EMA may require data from European
clinical trials before it approves of any
future hESC-derived therapy. Moreover,
recent studies suggest that over 50% of
products headed for FDA approval are in
clinical trials that involve foreign study
sites (Levinson, 2010).
Finally the possibility that some com-
panies could be attracted to Europe500 Cell Stem Cell 9, December 2, 2011 ª20because of this decision cannot be dis-
counted. Although the Court ruling does
not directly impact the patentability of
hESC inventions in the U.S., it will have
a ripple effect there. American companies
facing a freedom to operate problem
because of U.S. patents held by others
may now reconsider their business
plans. Moving their research operations
to Europe becomes a more attractive
option because the EU counterparts of
those patents are no longer enforceable.
These companies will balance the benefit
afforded by the new EU patent landscape
against the protection that the Hatch
Waxman Act provides for certain research
activities in the U.S. and the significant
costs of moving an already established
and ongoing research operation. A cost
differential that disfavors the U.S. as an
alternative to the EU may incentivize
companies to consider moving their trials
and preclinical efforts to places such as
India or China.
As Yogi Berra once said, ‘‘It’s tough to
make predictions, especially about the
future.’’ Everyone will need to wait and
see how various stakeholders in the
research community actually respond to
the Court’s ruling. Nevertheless, we are
confident that the reaction will be depen-
dent on many individual variables. As a
result, we expect that some of the
currently critical hESC researchanddevel-
opment in the EU will continue to flourish.11 Elsevier Inc.REFERENCES
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DOI 10.1016/j.stem.2011.11.007On October 18, 2011, the Court of Justice
of the European Union (CJEU) issued its
much anticipated and controversial deci-
sion in the case of Bru¨stle v. Greenpeace
(Court of Justice of the European Union,
2011). The Court ruled that inventions
involving human embryonic stem cells(hESCs) are unpatentable.While this deci-
sion is unhelpful for the field, its impact
may be more limited and nuanced than
others have suggested.
In brief, the case related to a patent filed
by Professor Oliver Bru¨stle in 1997 that
described and claimed the isolation andpurification of precursor cells generated
from hESCs. Greenpeace argued in pro-
ceedings launched initially in Germany in
2004 that this patent breached Article
6(2)(c) of the EU Biotechnology Directive,
which states that inventions involving the
‘‘use of human embryos for industrial or
